Evidence map›Paper›PMID 27942231›Full record

ReviewPharmacogenomics and personalized medicine2016

CYP2D6 polymorphisms and their influence on risperidone treatment.

Apichaya Puangpetch, Natchaya Vanwong, Nopphadol Nuntamool, Yaowaluck Hongkaew, Monpat Chamnanphon, Chonlaphat Sukasem

Open access · goldAbstract readReview
In one paragraph

Review in Pharmacogenomics and personalized medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Pharmacogenetic Approach to Tramadol Use in the Arab Population.International journal of molecular sciences · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Molecular Dysregulation in Autism Spectrum Disorder.Journal of personalized medicine · 2021
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Apichaya PuangpetchDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital.
Natchaya VanwongDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital.
Nopphadol NuntamoolMolecular Medicine, Faculty of Science, Mahidol University, Bangkok, Thailand.
Yaowaluck HongkaewDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital.
Monpat ChamnanphonDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital.
Chonlaphat SukasemDivision of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine Ramathibodi Hospital.
Ramathibodi Hospital · THMahidol University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytochrome P450 enzyme especially

Indexed as

adverse drug reactionCYP2D6pharmacodynamicspharmacogeneticspharmacokineticspolymorphismsrisperidone

Identifiers

PMID27942231
PMCPMC5138038
OpenAlexW2557740751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.